<DOC>
	<DOCNO>NCT00665223</DOCNO>
	<brief_summary>The purpose study determine ACR16 effective safe symptomatic treatment Huntington 's disease .</brief_summary>
	<brief_title>A Study Treatment With Pridopidine ( ACR16 ) Patients With Huntington 's Disease</brief_title>
	<detailed_description>The primary objective present study confirm whether ACR16 efficacious improve voluntary motor function Huntington 's disease , symptom seem important functional disability associate disorder . To achieve , patient randomise ACR16 45mg qd , ACR16 45mg bd , placebo treatment equal proportion parallel design treatment duration 26 week .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Able provide write Informed Consent prior study related procedure . Huntington 's disease diagnose aid clinical feature positive family history and/or presence ≥ 36 CAG repeat Huntington gene . Male female age ≥ 30 year . Willing able take oral medication able comply study specific procedure . Ambulatory , able travel assessment centre , judge Investigator likely able continue travel duration study . Availability caregiver family member accompany patient . A sum ≥ 10 point mMS screening visit . For patient take allow antipsychotic medication , dose medication must keep constant least 6 week randomisation . The allowed antipsychotic medication Amisulpride , Haloperidol , Olanzapine , Risperidone , Sulpiride , Tiapride . For patient take allow antidepressant psychotropic medication , dose medication must keep constant least 6 week randomisation . Willing provide blood sample CAG analysis ( CAG result already available ) . In France , patient must affiliate social security system beneficiary system . Unable give write informed consent . Treatment nonallowed antipsychotic medication within 12 week randomisation . The nonallowed antipsychotic medication medication Amisulpride , Haloperidol , Olanzapine , Risperidone , Sulpiride , Tiapride . Treatment antidepressant Fluoxetine Paroxetine within 6 week randomisation . Use Tetrabenazine within 12 week randomisation , time study period . Treatment investigational product within 4 week randomisation . Use tricyclic antidepressant , class I antiarrhythmics , strong CYP2D6 inhibitor Ajmalicine , Chinidin/Quinidine Ritonavir , within 6 week randomisation . Patients previously include study . A prolonged QTc interval screen ( define QTc interval &gt; 450 msec male &gt; 470 msec female ) , clinically significant heart condition . Creatinine clearance &lt; 40mL/min measure screening visit . Any clinically significant , abnormal , baseline laboratory result opinion Investigator , affect patient ' suitability study put patient risk he/she enters study . Clinically significant hepatic renal impairment . Patients history epilepsy history seizure ( ) unknown cause . Severe intercurrent illness , , opinion Investigator , may put patient risk participate trial may influence result trial affect patient ' ability take part trial . Alcohol and/or drug abuse define DSM IVTR criterion substance abuse include illicit use cannabis within last 12 month . Patients suicidal ideation , define positive score criterion major depressive episode , item A9 DSMIVTR criterion Major Depressive Episode . Females pregnant lactating . Females child bear potential take adequate contraceptive precaution exclude trial . Females child bear potential take acceptable contraceptive precaution include . Known allergy ingredient trial medication placebo . Any previous participation clinical study ACR16 . Patients currently receive deep brain stimulation . Patients history surgical procedure aim improve symptom Huntington 's disease , neural transplantation , lesion central nervous system , infusion neurotrophic agent previous attempt deep brain stimulation .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Huntington 's Disease</keyword>
</DOC>